{"url_path":"/sec/rani/8-k/2026-05-15/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1856725/0001193125-26-226691-index.html","accession_number":"0001193125-26-226691","cik":"0001856725","ticker":"RANI","issuer_name":"Rani Therapeutics Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1856725/0001193125-26-226691-index.html","primary_entity_key":"0001856725","primary_entity_name":"Rani Therapeutics Holdings, Inc."},"word_count":155,"has_tables":true,"body_markdown":"Item 2.02 Results of Operations and Financial Condition.\n\nOn May 15, 2026, Rani Therapeutics Holdings, Inc. (the “Company”) issued a press release providing a corporate update, announcing its financial results for the three months ended March 31, 2026, as well as a Chief Financial Officer transition. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\n \n\nThe information in Item 2.02, including the press release attached as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing."}